On August 3, AstraZeneca PLC fell 3.68% overnight, trading at $162.24/share, with turnover of $6.68 million. The decline came after reports emerged that the company is in discussions with Bristol-Myers Squibb over a potential merger that could create one of the largest pharmaceutical companies globally.

According to sources familiar with the matter, AstraZeneca has been exploring a combination with Bristol-Myers Squibb, with the merged entity potentially valued at approximately $400 billion. AstraZeneca currently carries a market capitalization of around $264 billion, while Bristol-Myers Squibb is valued at approximately $133 billion. Negotiations have reportedly been ongoing for several months, though significant uncertainty remains regarding whether the transaction will materialize.

Bristol-Myers Squibb is currently preparing for patent expirations on key products including blood thinner Eliquis and cancer drug Opdivo, which together account for roughly half of its sales revenue. The company recently reported record quarterly sales of $13 billion. The potential deal reflects the broader trend of large pharmaceutical companies pursuing M&A to bolster innovation pipelines amid rising R&D costs and patent cliffs.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)